heavily pretreated patients

Related by string. * HEAVILY . Heavily : heavily fortified Green . heavily armed . Heavily Indebted Poor . leaned heavily . leans heavily / pretreating : pretreating taxiways . docetaxel pretreated . pretreated roads . pretreat roads . pretreating roads / PATIENTS . PATIENT . Patients . pa tients : Breast Cancer Patients . terminally ill patients . Patient Safety . Improving Patient Outcomes * *

Related by context. Frequent words. (Click for all words.) 71 metastatic renal cell carcinoma 68 evaluable patients 67 bortezomib 66 evaluable 66 antitumor activity 66 unresectable 66 refractory multiple myeloma 65 tumor regression 65 chemoradiation 65 chemotherapy regimens 65 gemcitabine 65 trastuzumab 65 tumor shrinkage 65 vinorelbine 64 adalimumab 64 fluorouracil 64 fludarabine 64 sunitinib 64 mitoxantrone 64 HRPC 63 docetaxel 63 IMGN# 63 resistant ovarian cancer 63 topotecan 63 cyclophosphamide 63 erlotinib 63 chronic lymphocytic leukemia CLL 63 liver metastases 63 dasatinib 63 RECIST criteria 63 temozolomide 63 brain metastases 63 dose limiting toxicities 63 lupus nephritis 63 HGS ETR1 62 NSCLC 62 myelosuppression 62 adjuvant therapy 62 Cotara 62 FOLFOX 62 hematologic 62 rituximab 62 pemetrexed 62 taxanes 62 sorafenib 62 DMARDs 62 imatinib 62 zoledronic acid 61 vandetanib 61 bone metastasis 61 azathioprine 61 BAY #-# 61 mg BID 61 cetuximab 61 anthracycline 61 carboplatin 61 advanced NSCLC 60 gefitinib 60 chemotherapy regimen 60 tumor recurrence 60 CA4P 60 COPAXONE R 60 AP# [003] 60 castration resistant prostate cancer 60 monotherapy 60 sustained virologic response 60 mcg kg 60 CoFactor 60 Taxotere R 60 GvHD 60 peginterferon 60 free survival PFS 60 5 fluorouracil 60 placebo controlled trials 60 cytarabine 60 anti TNF 60 autologous stem cell 59 tolerability profile 59 follicular lymphoma 59 adjuvant chemotherapy 59 Xcytrin 59 plus ribavirin 59 chemotherapeutic agents 59 infliximab 59 soft tissue sarcomas 59 etanercept 59 Perifosine 59 taxane 59 HCV infected 59 Median survival 59 Bevacizumab 59 dose escalation 59 Phase 2a trial 59 hematologic malignancies 59 GRN#L 59 anthracyclines 59 melphalan 59 endocrine therapy 59 bevacizumab 59 raltegravir 58 HCV genotype 1

Back to home page